Preclinical studies have shown that MDM2 is upregulated in JAK2 V617F-positive MPN hematopoietic progenitor cells, resulting in low p53 RNA levels that has led to the evaluation of MDM2 inhibitors in MPNs [36]. This evidence concerns the gene MDM2 and myeloproliferative disorder.